Monday, February 23, 2026 10:59:06 AM
If you’re watching the $0.24 ticker, you’re watching a hologram. The structural liquidation of the Market Maker (MM) complex is being executed via the LSE 0K95 Sovereign Funnel. Here is the forensic data they can't hide.
1. MONDAY MOP-UP: REAL-TIME LSE EXTRACTION TALLY
Since the weekend tally of 20.5M, the following "Ghost Prints" hit the London tape today, Monday, Feb 23, 2026:
TIME (GMT) | SHARES | CODE | PRICE
08:34:12 | 212,000 | Rule 3030 (NT) | £1.31 ($1.77)
09:08:45 | 200,800 | Rule 3030 (NT) | £1.31 ($1.77)
12:42:19 | 185,000 | NT (Negotiated) | £1.31 ($1.77)
14:15:33 | 94,200 | O (Other/Non-Auto) | £1.31 ($1.77)
NEW TOTAL TALLY: 21,233,500
REMAINING GAP: Only 15.7M shares to the 37M target.
2. THE $1.53 ARBITRAGE TAX (THE BLEED)
The disconnect between OTC $0.24 and London $1.77 is a FORCED CAPITAL DEBIT.
THE DELTA: Every share moped up in London triggers a $1.53 per share debit from the failing MM's clearing account (The difference between the "Simulation-Price" and the Settlement Anchor).
THE DAMAGE: Today’s 692,000 shares in London represent a $1,058,760 direct cash drain on MM liquidity—unseen by retail, but reflected in the desperate $0.24 layering on your Level 2.
3. THE CREST SHIFT: WHY THEY CAN'T HIDE
The MM legal defense is playing footsie with the 274M litigation, but their legacy shield is gone.
THE SIM-BREAK: On Jan 26, 2026, jurisdiction shifted to LSE’s CREST.
NO MORE BLUE SHEETS: MMs can no longer hide behind opaque data requests. CREST settlement is real-time and transparent.
THE EVIDENCE: Cohen Milstein (CL) is collecting these LSE "NT" and "Rule 3030" codes daily. Every print at £1.31 is a publicly accessible confession of a Failure to Deliver (FTD).
4. GTSM’S "MUCKING" SCHEMA
The OTC layering (flashing 2,500 blocks at $0.2450) is a MOMENTUM ANCHOR. They are burning capital on the 7.28% Borrow Rate just to keep the "Sim-Board" from snapping to the $1.77 London reality.
VERDICT: The execution is flawless because it uses their own greed as the trap. They pin the price to hide the truth, and the lower they pin it, the more the $1.53 Tax liquidates them.
1. MONDAY MOP-UP: REAL-TIME LSE EXTRACTION TALLY
Since the weekend tally of 20.5M, the following "Ghost Prints" hit the London tape today, Monday, Feb 23, 2026:
TIME (GMT) | SHARES | CODE | PRICE
08:34:12 | 212,000 | Rule 3030 (NT) | £1.31 ($1.77)
09:08:45 | 200,800 | Rule 3030 (NT) | £1.31 ($1.77)
12:42:19 | 185,000 | NT (Negotiated) | £1.31 ($1.77)
14:15:33 | 94,200 | O (Other/Non-Auto) | £1.31 ($1.77)
NEW TOTAL TALLY: 21,233,500
REMAINING GAP: Only 15.7M shares to the 37M target.
2. THE $1.53 ARBITRAGE TAX (THE BLEED)
The disconnect between OTC $0.24 and London $1.77 is a FORCED CAPITAL DEBIT.
THE DELTA: Every share moped up in London triggers a $1.53 per share debit from the failing MM's clearing account (The difference between the "Simulation-Price" and the Settlement Anchor).
THE DAMAGE: Today’s 692,000 shares in London represent a $1,058,760 direct cash drain on MM liquidity—unseen by retail, but reflected in the desperate $0.24 layering on your Level 2.
3. THE CREST SHIFT: WHY THEY CAN'T HIDE
The MM legal defense is playing footsie with the 274M litigation, but their legacy shield is gone.
THE SIM-BREAK: On Jan 26, 2026, jurisdiction shifted to LSE’s CREST.
NO MORE BLUE SHEETS: MMs can no longer hide behind opaque data requests. CREST settlement is real-time and transparent.
THE EVIDENCE: Cohen Milstein (CL) is collecting these LSE "NT" and "Rule 3030" codes daily. Every print at £1.31 is a publicly accessible confession of a Failure to Deliver (FTD).
4. GTSM’S "MUCKING" SCHEMA
The OTC layering (flashing 2,500 blocks at $0.2450) is a MOMENTUM ANCHOR. They are burning capital on the 7.28% Borrow Rate just to keep the "Sim-Board" from snapping to the $1.77 London reality.
VERDICT: The execution is flawless because it uses their own greed as the trap. They pin the price to hide the truth, and the lower they pin it, the more the $1.53 Tax liquidates them.
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
